Article
Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2014
Ono A, Kenmotsu H, Watanabe M, Serizawa M, Mori K, Imai H, Taira T, Naito T, Murakami H, Nakajima T, Ohde Y, Endo M, Yamamoto N, Koh Y, Takahashi T
Abstract excerpt
BACKGROUND: Whether the mutant allele frequency (MAF) may also have predictive implications for tyrosine kinase inhibitor (TKI) therapy in patients with advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma (AELAd) remains unknown. PATIENTS AND METHODS: Based on a biobanking system in conjunction with our institution, we assessed EGFR mutation status using pyrosequencing (Py) and by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.